{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:59:44Z","timestamp":1787507984883,"version":"build-2736575974"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alopecia areata (AA), especially very severe types, causes patients severe psychological and social distress. Although baricitinib alone has been shown to be effective in conferring complete hair regrowth (HR) in severe AA [Severity of Alopecia Tool (SALT) score 50\u201394], it gave poor therapeutic results in very severe AA (SALT score \u2265 95). Methotrexate alone is similarly ineffective, but in a recent study of patients with areata totalis or universalis, low-dose prednisone with methotrexate gave a 20% rate of HR, and was effective and well tolerated. In our study of baricitinib 4\u2005mg + prednisone 20\u2005mg per day tapered over 3\u2005months to treat eight women with very severe AA, seven of eight achieved complete HR (SALT score 0) and one had partial HR (SALT score 30).<\/jats:p>","DOI":"10.1093\/ced\/llad239","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T21:07:07Z","timestamp":1689800827000},"page":"1258-1259","source":"Crossref","is-referenced-by-count":13,"title":["Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9071-2033","authenticated-orcid":false,"given":"Vivien","family":"H\u00e9bert","sequence":"first","affiliation":[{"name":"Department of Dermatology, French Reference Centre for Autoimmune Bullous Diseases, University Hospital of Rouen, University\u00a0of\u00a0Rouen Normandy , Rouen , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[{"name":"Department of Dermatology, French Reference Centre for Autoimmune Bullous Diseases, University Hospital of Rouen, University\u00a0of\u00a0Rouen Normandy , Rouen , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"2023102519564065700_llad239-B1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","article-title":"Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families","volume":"79","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023102519564065700_llad239-B2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"2023102519564065700_llad239-B3","doi-asserted-by":"crossref","first-page":"AB52","DOI":"10.1016\/j.jaad.2022.06.243","article-title":"33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: results from BRAVE-AA1 and BRAVE-AA2","volume":"87","author":"Taylor","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2023102519564065700_llad239-B4","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/archderm.1992.01680210045005","article-title":"Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata","volume":"128","author":"Olsen","year":"1992","journal-title":"Arch Dermatol"},{"key":"2023102519564065700_llad239-B5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2005.09.010","article-title":"The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis","volume":"55","author":"Joly","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2023102519564065700_llad239-B6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1001\/jamadermatol.2022.6687","article-title":"Efficacy of methotrexate alone vs methotrexate plus low-dose prednisone in patients with alopecia areata totalis or universalis: a 2-step double-blind randomized clinical trial","volume":"159","author":"Joly","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2023102519564065700_llad239-B7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad239\/51089606\/llad239.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/11\/1258\/52548787\/llad239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/11\/1258\/52548787\/llad239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T15:57:49Z","timestamp":1698249469000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/11\/1258\/7226662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":7,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,7,20]]},"published-print":{"date-parts":[[2023,10,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad239","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,7,20]]}}}